Bladder Cancer

Tecentriq (Atezolizumab) Receives New Indication for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

Lisa A. Raedler, PhD, RPh

2018 Third Annual Oncology Guide to New FDA Approvals - Bladder Cancer, FDA Approvals, News & Updates

Urothelial carcinoma is the most common subtype of bladder cancer, accounting for more than 90% of bladder cancer diagnoses in the United States. In 2017, more than 79,000 bladder cancer cases were diagnosed in the United States, and more than 16,000 people died from this disease. The prognosis is favorable for patients with localized disease, with a 5-year relative survival rate of 78% for all stages of bladder cancer, which decreases to 5% for patients with distant disease. [ Read More ]

Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer

Lisa A. Raedler, PhD, RPh

2018 Third Annual Oncology Guide to New FDA Approvals - Bladder Cancer, FDA Approvals, News & Updates

Urothelial carcinoma is the primary subtype of bladder cancer, which is the sixth most common cancer in the United States. More than 79,000 cases of bladder cancer were estimated to be diagnosed, and nearly 17,000 people to die from this disease in 2017. [ Read More ]

Hispanics More Likely than Caucasians to Develop Major Complications after Radical Cystectomy

Rosemary Frei, MSc

November 2013, Vol 4, No 9 - Bladder Cancer

Vancouver, Canada—The odds of having a major complication after a radical cystectomy, which is performed as part of the treatment for bladder cancer, are higher for Hispanics than for Caucasians, researchers have found. They calculated that the rate of such complications was 23.53%  for Hispanic Americans compared with 16.09% for Caucasian Americans.

[ Read More ]